Hexagon Investments

Hexagon Bio is a data-driven biopharmaceutical company based in Menlo Park, California, that leverages a proprietary platform to discover novel medicines from the global metagenome. By combining machine learning, genomics, and synthetic biology, the company mines microbial genomes—specifically from fungi and bacteria—to identify evolutionarily refined small molecules and their corresponding protein targets. Hexagon's primary focus is on developing next-generation antibody-drug conjugates (ADCs) with novel payloads, such as protein translation inhibitors, to overcome resistance in oncology and infectious diseases. The company has built a massive proprietary database of microbial genomes, significantly larger than public repositories, to fuel its drug discovery engine. Hexagon Bio has raised over $200 million from top-tier investors and recently established a major joint venture with Corteva to apply its platform to both human health and sustainable agriculture.